Abstract

This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS Phase I:1. To define the maximum tolerated dose (MTD) of OSI-774 (erlotinib; TarcevaTM) in combination with CCI-779 (temsirolimus) in patients with recurrent malignant glioma who are not taking enzyme-inducing anti-epileptic drugs (EIAEDs). 2. To characterize the safety profile of OSI-774 (erlotinib) and CCI-779 (temsirolimus). 3. To characterize the pharmacokinetics of OSI-774 (erlotinib) and CCI-779 (temsirolimus). Phase II:Primary Aim:1. To determine the efficacy of OSI-774 (erlotinib) and CCI-779 (temsirolimus) in patients with recurrent malignant glioma as measured by 6-month progression-free survival.Secondary Aims:1. Overall progression-free survival2. ResponseExploratory Aims:1. To explore the association of response to treatment to the molecular phenotype of the tumor. 2. Determine whether OSI-774 (erlotinib) and CCI-779 (temsirolimus) inhibits EGFR and mTOR and the PI3K-AKT-mTOR and RAS-ERK signaling pathways in tumor specimens taken from malignant glioma patients undergoing surgery. 3. Tumor concentration of OSI-774 (erlotinib) and CCI-779 (temsirolimus).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000865-35
Application #
7717999
Study Section
Special Emphasis Panel (ZRR1-CR-4 (01))
Project Start
2007-12-01
Project End
2008-11-30
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
35
Fiscal Year
2008
Total Cost
$12,120
Indirect Cost

  Institution

Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095

  Publications

Nersesian, Paula V; Han, Hae-Ra; Yenokyan, Gayane et al. (2018) Loneliness in middle age and biomarkers of systemic inflammation: Findings from Midlife in the United States. Soc Sci Med 209:174-181
Glei, Dana A; Goldman, Noreen; Ryff, Carol D et al. (2018) Physical Function in U.S. Older Adults Compared With Other Populations: A Multinational Study. J Aging Health :898264318759378
Stephan, Yannick; Sutin, Angelina R; Bayard, Sophie et al. (2018) Personality and sleep quality: Evidence from four prospective studies. Health Psychol 37:271-281
Green, Shulamite A; Hernandez, Leanna M; Bowman, Hilary C et al. (2018) Sensory over-responsivity and social cognition in ASD: Effects of aversive sensory stimuli and attentional modulation on neural responses to social cues. Dev Cogn Neurosci 29:127-139
Ellsworth, G B; Lensing, S Y; Ogilvie, C B et al. (2018) A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men. Papillomavirus Res 6:11-14
Goldman, Noreen; Glei, Dana A; Weinstein, Maxine (2018) Declining mental health among disadvantaged Americans. Proc Natl Acad Sci U S A 115:7290-7295
Dean, Andy C; Morales, Angelica M; Hellemann, Gerhard et al. (2018) Cognitive deficit in methamphetamine users relative to childhood academic performance: link to cortical thickness. Neuropsychopharmacology 43:1745-1752
Ringman, John M; Casado, Maria; Van Berlo, Victoria et al. (2017) A novel PSEN1 (S230N) mutation causing early-onset Alzheimer's Disease associated with prosopagnosia, hoarding, and Parkinsonism. Neurosci Lett 657:11-15
Schwartz, Joseph A (2017) Long-term physical health consequences of perceived inequality: Results from a twin comparison design. Soc Sci Med 187:184-192
Bei, Bei; Seeman, Teresa E; Carroll, Judith E et al. (2017) Sleep and Physiological Dysregulation: A Closer Look at Sleep Intraindividual Variability. Sleep 40:

Showing the most recent 10 out of 1085 publications